Mast cell–nerve axis with a focus on the human gut  by Buhner, Sabine & Schemann, Michael
Biochimica et Biophysica Acta 1822 (2012) 85–92
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbadisReview
Mast cell–nerve axis with a focus on the human gut☆,☆☆,★
Sabine Buhner, Michael Schemann ⁎
Human Biology, Technische Universität München, Germany☆ This article is part of a Special Issue entitled: Mas
☆☆ Grant support: This study is supported by the EU
the Deutsche Forschungsgemeinschaft DFG Sche-267/7-
★ Financial disclosure: None to disclose; Conﬂicts:
⁎ Corresponding author at: Human Biology, Tech
Liesel-Beckmann-Strasse 4, 85350 Freising-Weihenstep
715483; fax: +49 8161 715785.
E-mail address: schemann@wzw.tum.de (M. Schem
0925-4439/$ – see front matter © 2011 Elsevier B.V. Al
doi:10.1016/j.bbadis.2011.06.004a b s t r a c ta r t i c l e i n f oArticle history:
Received 21 February 2011
Received in revised form 7 June 2011
Accepted 10 June 2011
Available online 17 June 2011
Keywords:
Mast cell
Enteric nervous system
Viszeral afferents
Human
Neuro-immune interactionThis paper summarizes the current knowledge on the interactions between intestinal mast cells, enteric
neurons and visceral afferents which are part of the gut brain axis. The focus of this review is on the relevance
of the mast cell–nerve axis in the human intestine. Similarities and important differences in the organization
of the mast cell–nerve axis between human and rodents are discussed. Functionally important human mast
cell mediators with neural actions in the human ENS are histamine (H1-4 receptors), proteases (PAR1
receptors), several cytokines and chemokines and probably also serotonin (5-HT3 receptors). On the other
hand, mediator release from human intestinal mast cells is modulated by neuropeptides released from enteric
and visceral afferent nerves. This article is part of a Special Issue entitled: Mast Cells in Inﬂammation.t Cells in Inﬂammation.
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Over the last decades neuroimmune interactions in the gut became
a hot topic in neurogastroenterology. The components consist of
different systems including various immune cells and the enteric
nervous system aswell as extrinsic vagal or spinal afferent nerves. The
current concepts on neuroimmune interactions in the gut are almost
exclusively based on data from cellular or organ responses in animal
models. A number of recent reviews elegantly summarized such
ﬁndings and the interested reader is referred to them [1–5]. We like to
review primarily the evidence for the functional mast cell–nerve axis
in the human gut. However, we will also point out ﬁndings from
animal studies if they are particularly pertinent with respect to trans-
lation to the human gut or to stress the relevance for similar mecha-
nistic studies in the human gut.
2. The enteric nervous system
The concept of a "brain in the gut" emerged in the early 1900s.
Subsequently, neurochemical, neurobiological and functional studies
have conﬁrmed that the enteric nervous system (ENS) closely
resembles the central nervous system. The ENS contains about
100 million nerve cells within the gut wall. It regulates autonomouslymost of the physiological functions of the gastrointestinal tract for
example motility, secretion, microcirculation as well as immune
function and thereby inﬂammatory processes. The basic organization
and function of the ENS in all mammals is much the same. The enteric
neurons are anatomically and functionally organized into three major
plexuses, the myenteric, the submucous and the mucous plexus. The
myentric plexus is positioned between the longitudinal and the
circular muscle layers and plays an important role in regulating gut
motility. The submucous plexus, being prominent only in the
intestine, is located between the circular muscle layer and the
mucosa. In larger species it consists of two and in human of at least
three ganglionated layers. Together with the mucous plexus it is
mainly involved in the interplexal communication and secretory
functions. The ENS communicates with the central nervous system
through sympathetic and parasympathetic efferent neurons as well as
through afferent neurons which run together with parasympathetic
or spinal nerve bundles [6–9]. Both efferent and afferent nerve ﬁbers
ramify substantially once they enter the gut wall. They can thereby
make not only contact with enteric neurons but also with immune
cells including mast cells. The functional consequence of this close
anatomical association is that neurons and immune cells act as a
surveillance network.
In general, the neurochemistry in the human ENS is as complex as
in other species [10–12]. More than two dozens of putative neuro-
transmitters have been described. Neurons usually express a
combination of different neurotransmitters. A few substances serve
as primary transmitters which are more or less uniformly found in the
same groups of enteric neurons across the species, e.g. acetylcholine
(ACh), serotonin (5-HT), substance P (SP), and vasoactive intestinal
polypeptide (VIP). Data available on electrophysiological properties of
the human enteric neurons are still rare. Work of the last decade
Table 1
Human mast cell mediators.
Preformed in granules De novo synthesized
Enzymes/proteoglycans Cytokines and growth factors
Heparin IL-1, IL-1R antagonist, IL-3, IL-4a, IL-5, IL-6, IL-8, IL-9, IL-10,
IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-18, TNFα, TNFβ,
INFα, basic FGF, VEGF, NGF, NT-3, LIF, LTβ, GM-CSF, M-CSF,
MIF, SCF, EGF, PDGF-AA, PDGF-BB,
Chondroitinsulfates
Tryptases (α, β, γ)
Chymase
Carboxypeptidase-A
Cathepsin
Major basic protein
Histamine Eicosanoids
PGD2, LTB4, LTC4, LTD4, PAF
Chemokines
CCL1, CCL2 (MCP-1), CCL3 (MIP-1α), CCL3L1, CCL4 (MIP-
1β), CCL5, CCL7, CCL8, CCL11, CCL13, CCL16, CCL17,
CCL20, CCL22, CXCL1, CXCL2, CXCL3, CXCL10, XCL1,
Others
Nitric oxide, superoxide, CRF, urocortin
Some cytokines and growth factors can be both, released from preformed pools and
newly synthesized (e.g. TNF and VEGF). Table is based on data summarized in Refs.
[18,19,127,128].
a IL-4 production seem to be restricted to mast cells of allergic persons [126].
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recording technique (MSORT) opened a way to directly study ENS
activity from human tissues which was not possible up till then [13].
3. The mast cell
3.1. Mast cell origin
Cells of the mucosal immune system are typically classiﬁed as
belonging to either the adaptive or the innate immune system. Mast
cells are part of the innate immune system that provides theﬁrst line of
defense against threatening environmental inﬂuences. In addition to
their prominent role in immunoglobulin E (IgE)-dependent hyper-
sensitivity, mast cells release and modulate the release of cytokines,
growth factors, chemokines and other mediators, which in turn
regulate multiple important biological processes. Mast cells are
located in tissues that form large host barriers such as skin, respiratory
and intestinal mucosa. In the human gastrointestinal tract mast cell
density is highest in the lamina propria mucosae, where they amount
to 2–3% of all cells, and slightly less (about 1% of all cells) in the
submucosa. In the muscle layers or in the serosa they occur only
sporadically in healthy individuals [14].
Mature mast cells show a strong species and organ speciﬁc
heterogeneity concerning morphology, biochemical properties and
function. Their development, differentiation, and functional reactivity
are critically dependent on the microenvironment. Mast cells are
extremely plastic and adapt synthesis and release of their mediators
to tissue conditions. Thus when comparing research data on mast
cells, the mast cell source and the particular maturation stage must be
always kept in mind, and, most importantly, should be speciﬁed [15–
17]. This is of special importance in terms of the profound species
difference in mast cell properties between humans and rodents
[18,19]. Since rodents represent the main animal models for
immunological as well as neurophysiological studies, translation of
data to human is difﬁcult. Thus the tools in human mast cell research
should be chosen with caution. Different methods and techniques
have been recently reviewed and discussed in detail as for example
the preparation of human cord blood cells, or mast cell lines as the
non-transformed leukemia derived cell lines [18]. However, for
studies on human intestinal mast cells, primary cultures of mast
cells isolated from solid tissues seem to be a very important tool [18].
3.2. Mast cell activation
Mast cells exert their biological functions almost exclusively by the
release of mediators after activation. Generally, the classical and most
effective activation of mast cells occurs by interaction of a multivalent
antigen with its speciﬁc IgE antibody bound to the cell membrane via
the high-afﬁnity receptor FcεRI. The knowledge on IgE independent
triggers of mast cell activation, especially in humans, is very limited
[19]. There are reports on Toll-like receptor mediated effects but also
non-Toll-like receptor mediated effects as cholera toxin and α-
haemolysin mediated human mast cell activation [20–22]. The role
of cytokines seems to be of particular importance. Human mast cells
challenged to interferon γ (IFNγ) express FcγRI at sufﬁcient levels to
enhance mediator release [23]. Other mediators as anaphylatoxins
(C3a, C5a), nerve growth factor (NGF), interleukin 8 (IL-8) or the
neuropeptide SP only affect human skin mast cells but failed to show
effects on isolated human mucosal mast cells [24,25]. However, if
primed by growth factors such as stem cell factor (SCF) and IL-4 these
cells start to express neurokinin 1 (NK1) receptors and under these
conditions then respond to SPwith increasedmediator release [24,26].
Co-stimulatory signals from other substances in the milieu must be
considered. Sometimes, as in the case of IL-4, cytokines may not act
directly but synergisticallywith SCF to enhancemast cell development
and to alter mediator release [27–30]. In rodents similar mechanismshave been recently shown for the macrophage inﬂammatory protein-
1α (MIP-1α) [31]. In mice MIP-1α is required for an optimal mast cell
degranulation. Also inhibitory mechanisms, balancing the agonistic
activity have been reported. For example, Transforming growth factor
beta 1 (TGF-β1) dose dependently inhibited SCF dependent growth of
human intestinal mast cells by both enhancing apoptosis and
decreasing proliferation [32]. Similar inhibitory effects have been
shown in human cord blood-derived mast cells for IL-10 and β2-
adrenoceptor agonists [33].
The strikingly high number and diversity of mediators released
from human mast cells reﬂect their broad actions in a wide variety of
physiological and pathophysiological functions (Table 1). The medi-
ators can be subdividedmainly into two classes. Theﬁrst class includes
signaling molecules that are preformed, stored as granules and can
therefore be released within seconds, this is the case for as histamine,
proteases and to some degree for tumor necrosis factor α (TNFα).
Others are newly synthesized when mast cells become activated such
as lipid mediators and most cytokines. Thus degranulation of mast
cells produces a microenvironment which may in turn feed back and
inﬂuence the degree of activation of mast cells. For example in human
intestinal mast cells TGF-β1 was found to inﬂuence the mediator
proﬁle by reducing histamine, cysteinyl-leukotrienes, and TNFα
release whereas prostaglandin D2 (PGD2) generation and cyclooxy-
genase 1 and 2 expression were up regulated [32].
4. Signaling from nerves to mast cells: nerve–mast cell signaling
Extrinsic afferent nerves, in addition to transmit information to the
central nervous system, carry out many local effector functions
through axon collaterals within the gut wall. Endings of extrinsic
afferent nerves as well as enteric neurons are in close proximity to
mast cells (Fig. 1). An estimated 70% of intestinal mucosal mast cells
are in direct contact with nerves, and another 20% are within 2 μm
[34,35]. This anatomical association has functional relevance as com-
munication between nerves and mast cells is crucial for maintaining
mucosal homeostasis and for ensuring an appropriate response to
injury.Mast cells respond to neurotransmitters andnerves thereby can
regulate their activation threshold [36]. A preliminary study in guinea-
pig ileum and colon preparations provided direct evidence for a spinal
afferent–mast cell–ENS interaction [37]. The authors found that
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Fig. 1. Immunohistochemical demonstration of mast cell nerve interactions and mast cell phenotype in the human colon. (A): A section through the colon wall stained for the
panneuronal marker PGP9.5 (in green) and mast cell tryptase (blue). Note the gradient of mast cells with the highest density in the epithelial/subepithelial layer. (B): A high power
magniﬁcation of a region shown in (A) illustrating the close association between mast cells and nerves. (C) is a labeling in a whole mount illustrating the close association between
enteric neurons (PGP9.5 in green), mast cells (in blue) and nerve endings of visceral afferents labeled with a TRPV1 antibody (in red). Note the two mast cells nearby the small
enteric ganglion and the TRPV1 nerve ﬁber. (D–F) demonstrate the lack of serotonin staining (in red) in mast cells which have been labeled with mast cell tryptase (blue color in D
and E) or c-kit (blue color in F and G). The staining with a serotonin antibody revealed enterochromafﬁne cells (EC cells). E and G are magniﬁed regions from D and F, respectively.
Note that no mast cell is serotonin-positive. SMP = submucous plexus; CM = circular muscle; MP = myenteric plexus.
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which in turn activate submucous neurons through the protease-
activated receptor 1 (PAR1) and PAR2.
The enormous variety of responsepatterns is suggested to bedue to
species and organ speciﬁc properties. At the same time, themast cell is
viewed as an enormously plastic and adaptable cell type changing its
phenotype with alterations in issue conditions, pathological states or
modes of stimulation. Moreover, studies reporting on mast cell
mediator release are based on experiments with cell lines, isolated
and cultured mast cells, tissue mast cells or indirectly suggested by
pharmacological intervention with mast cell mediator actions on end
organ responses or animal behavior. It therefore needs to be
considered that not all the different behavior of rodent versus
human intestinal mast cells is due to different intrinsic or genotypic
properties. Rodent mucosal mast cells respond to adenosine triphos-phate (ATP), somatostatin, calcitonin gene-related peptide (CGRP)
and SP [2–4,24]. In contrast, in isolated cultured human intestinal
mucosal mast cells most of these neuropeptides and transmitters had
no effect on histamine release [24]. Experimental conditions may
partly explain the differences. For example, when primed by SCF or
IL-4 intestinal mast cells start to express NK1 receptors and respond to
SP with degranulation and mediator release [26].
There is strong evidence for functional relevance of such a
“sensitizing milieu”. Incubation of colorectal biopsies from patients
with active Crohn's Disease (CD) or Ulcerative Colitis (UC) with SP
inducemast cell degranulation andhistamine release from inﬂamedand
not-inﬂamed tissue [38]. However, in a smaller patient group, thesedata
could not be conﬁrmed [24]. Others suggested that SP inducedmucosal
mast cell degranulation may be mediated by a receptor independent
mechanism [39]. Other studies stress an increase in SP positive neurons
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patients with irritable bowel syndrome (IBS) [40–42]. Interestingly, in
cases of coexistence of IBS with interstitial cystitis a similar association
between SP positive nerves andmast cell was found in the bladder wall
[41]. In a rodent model the use of an NK1 receptor blocker or the
blockade of enteric neurotransmission with tetrodotoxin (TTX), as well
as the application of a mast cell stabilizer prevented the acute
inﬂammatory response to Clostridium difﬁcile toxin A [43–46]. In a
murine colitis model the administration of NK1 receptor antagonist
prevented among other signs of inﬂammation mucosal inﬁltration by
mast cells [47]. Therefore, as suggested by Barbara et al. 2006 [48], it
seems that mast cells are attracted by nerves upon the release of
neuropeptides. Data so far support the concept that SP plays a role in the
signal transmission from enteric neurons to mast cells in humans.
Whether or not this mechanism is receptormediated (NK1) or receptor
independent remains to be clariﬁed. The classical concept would
suggest that SP is released from enteric neurons or extrinsic afferents
nerves. However, a population of tryptase containing human intestinal
mast cells expresses SP [49]whichmay also suggest a possible autocrine
action of SP.
Considerable evidence suggests that also the neuropeptide VIP
plays a role in pathology of inﬂammatory bowel diseases [2,11,50,51].
A signiﬁcant increase in VIP content [52] and an increase in the
population of VIP positive neurons have been shown in colonic
biopsies of patients with Crohn's disease [11]. The latter study
additionally describes a pronounced hypertrophy of CGRP positive,
putative extrinsic sensory neurons. In inﬂammatory bowel diseases
(IBD) the number and reactivity of enteric mast cells are increased.
However direct effects of VIP or CGRP on human enteric mast cells are
unknown. In mice CGRP was found to degranulate mucosal mast cells.
[53]. Studies in rodents provide evidence for direct effects of various
neuropeptides on mast cells, e.g. for ATP, which mediates mast cell
degranulation or somatostatin which has an inhibitory inﬂuence on
mast cells in rats [54].
5. Stress and mast cell signaling
Stress is associated with gastrointestinal symptoms such as
diarrhea or abdominal pain. A brain–mast cell interaction is one
plausible mechanism linking stress and gastrointestinal symptoms. In
rodentsmanyﬁndings support the concept of a CNS–mast cell axis and
the role of the cholinergic enteric or vagal nerves in these pathways
(recently reviewed in detail [55]). In humans the release of mast cell
proteases into the lumen of the small intestine occurs as a conditioned
response to cold pain stress. The stress induced release of tryptase and
histamine, but not PGD2, was larger in food-allergic patients than in
healthy volunteers [56]. Central nervous inﬂuences on intestinal mast
cells could be mediated by extrinsic sensory nerves. While an
activation of sympathetic neurons certainly accounts for the cardio-
vascular symptoms associated with stress, degranulation of human
enteric [57] and lungmast cells [58] is rather prevented thanpromoted
by sympathetic activation. In isolated human intestinal mast cells
catecholamines and β2 adrenoreceptor agonists suppress the IgE
dependent release of mediators as well as mast cell proliferation and
migration [59]. In contrast, vagal stimulation in rodents [55,60] or ACh
application to human lung mast cells [61] promote histamine release
frommast cells. It is known, that also the corticotropin releasing factor
(CRF) is mainly involved stress induced alterations of gut functions
[62]. Cultured humanmast cells (leukemicmast cell line and umbilical
cord blood-derived mast cells) express CRF receptors, activation of
which led to a release of mast cell mediators [63].
6. Signaling from mast cells to nerves: mast cell–nerve signaling
The mast cell–ENS axis combines specialized memory and sensory
functions of the enteric mast cells with the capacity of the ENS tointegrate paracrine signals. The role of the mast cell is twofold. On one
hand it operates as a sensory cell activated by both immune and non-
immune stimuli, and at the same time it acts as an effector cell
releasing a number of highly biologically active mediators [64]. These
substances serve as paracrine signals to extrinsic and intrinsic neural
networks in the gut wall which in turn respond by initiating defense
programs. A classical example for such a communication between
mucosal mast cells and enteric neurons is the hypersensitivity
reactions associated with food allergy. The mechanisms have been
elegantly studied in a guinea pig model with antigen sensitization to
cow's milk [65–69]. These data are relevant for similar interactions in
the humangut. An antigen-evokedmast cell degranulation in the small
and large intestine starts an immediate reaction characterized by
mucosal hypersecretion [67,69] and strong muscle contractions [70].
The application of TTX suppresses the response clearly demonstrating
the participation of neurons. Electrophysiological methods were used
to investigate electrical and synaptic behavior of intestinal neurons
during antigen exposure in milk sensitized guinea pigs. The applica-
tion of the antigen to sensitized preparations strongly increased the
neuronal activity in secretomotor neurons of the ENS. The effects were
inhibited by amast cell stabilizer, a histamineH2 receptor antagonist, a
cyclooxygenase (COX) or a lipoxygenase inhibitor [68].
Augmented stimulation of secretomotor neurons may be also
involved in the secretory diarrhea associated with food allergy in
humans [5]. This is supported by the therapeutic success of usingmast
cell stabilizers like ketotifen to reduce the gastrointestinal symptoms
in food allergy [19,71]. Recently we provided further evidence for a
mast cell–ENS interaction in humans [72]. In this study we applied a
mast cell mediator “cocktail”, which was released from isolated
human intestinal mast cells by IgE receptor cross linking, onto human
enteric neurons. The “cocktail” evoked a strong neuronal excitation in
preparations of human and guinea pig submucous plexus [72]. The
prominent excitatory effects agree with the hyperexcitable state of
enteric nerves in the inﬂamed gut [73]. Interestingly, neurons in the
guinea pig myenteric plexus were less sensitive than those in the
submucous plexus [72] which may be related to the fact that mast
cells are rarely present in the myenteric plexus layer under normal
conditions. However, in the submucous layer there are numerous
mast cells and it seems plausible that neurons in this area should be
prepared to respond to a mast cell mediator cocktail.
The most important mast cell mediator is histamine. Since only
mast cells and basophilic cells contain histamine inman and only a few
basophile are present in the humanmucosa, histamine can be used as a
marker for mast cell degranulation. The pathophysiological relevance
of histamine has been frequently shown in allergic and non-allergic
diseases including gastrointestinal diseases such as IBD and IBS
[18,38,64,74–78]. In the human intestine histamine inﬂuences a
variety of gut functions including ﬂuid and ion transport [79–81]
which is partly nervemediated [79]. Histamine directly excites human
submucous neurons [82]. This effect wasmediated by the activation of
the four histamine receptor subtypes H1, H2; H3 and H4. The
application of receptor speciﬁc agonists revealed receptor clustering
on submucous neurons showing most frequently H1/H3 (29%), H2
(27%) and H1/H2/H3 (20%) clusters. Most striking was the identiﬁca-
tion of an excitatory H3 mediated component in humans submucous
neurons while H3 receptors mediate suppression of fast synaptic
transmission in the guinea-pig submucous plexus [82]. In rodents
histamine had been demonstrated to act on presynaptic H3 receptors
to suppress the release of acetylcholine and somatostatin from enteric
neurons as well as the release of noradrenalin from sympathetic
terminals [83–86]. The plasticity in histamine receptor expression in
patients with food allergy and IBS, in particular an increase in H1 and
H2 receptor mRNA levels, emphasizes the potential clinical beneﬁt of
drugs that act on histaminergic pathways [87]. Information on the
effects of histamine on extrinsic sensory neurons of the gut derives
exclusively from studies in rodents [4]. In rats H1 receptors have been
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shown that histamine or serotonin application to rat dorsal root
ganglion cells with projections to the viscera increased the Ca2+
responses to a TRPV4 (transient receptor potential cation channel
subfamily V member 4) agonist and enhanced the TRPV4 expression
[89]. TRPV4 is known to be involved in visceral hypersensitivity.
Sensitization of extrinsic afferent neurons by mast cell mediators
in particular histamine and proteases has been demonstrated in
animal models. Similar mechanisms may also be operative in the
human gut [90–92]. Application of an “inﬂammatory soup” composed
of PGE2, histamine, serotonin, ATP, adenosine and bradykinin
increased the spiking activity of afferents nerves [91].
Another group of mast cells mediators comprises the prostaglan-
dins (PGs) and leukotrienes (LTs) which are synthesized from the
precursor arachidonic acid by cyclooxygenase and lipoxygenase
enzymes, respectively. Among these substances PGD2 is the dominant
prostanoid and LTC4, LTD4, and LTE4 are the most prevalent
leukotrienes produced by human mast cells [19,93]. It was shown in
rodents that each of these mediators strongly stimulate intestinal
secretion [94]. These effects were partly mediated by direct actions on
enteric neurons. Intracellular recordings in guinea pig submucous
plexus revealed an activation of the neurons by all the mediators [95].
Whether similar mechanisms are active in humans is unclear. How-
ever, PGD2 receptors (DP) have been localized within the mucous-
secreting goblet cells of the human colon [96]. Recently an inducible
system for PGE2 generation in cultured human cord blood mast cells
was detected and described [97]. Since PGE2 plays amajor role in non-
allergic diseases similar studies in human enteric mast cells would be
interesting.
A variety of different cytokines, chemokines and growth factors
has been identiﬁed in human mast cells (Table 1). Most of them are
not stored preformed but synthesized de novo in active mast cells.
There is evidence that IL-1β and TNFα, but not IFN-γ, IFN-α, IL-6 or
IL-8 exhibit prosecretory effects in the human distal colon [98]. The
effects were TTX insensitive but could be blocked by indomethacine.
This indicates an additional effect of prostaglandins rather than anFig. 2. Schematic illustration of mast cell nerve interactions in the human gut based on stain
account themast cell gradient along the gut wall with the highest density in the epithelial/sub
Smaller fonts illustrate smaller contribution of the receptor. On the other hand, neurotrans
release (↑ increase; ↓ decrease).involvement of the ENS in this mechanism. In guinea-pig submucous
and myenteric neurons IL-1β induced an indomethacine sensitive c-
Fos expression [94] suggesting an indirect effect on the ENS which
involves prostaglandins. Results from human submucous neurons
demonstrated a direct excitatory action of IL-1β on enteric neurons
[99]. Further knowledge on the inﬂuence of cytokines on enteric
neurons derives from studies in laboratory animals. Frequently
studied substances are IL-1β and IL-6. Both are reported to increase
excitability in submucous and myenteric neurons and to mediate
effects on cholinergic and non-cholinergic transmission [100–102]. IL-
1β also sensitizes extrinsic visceral afferents of cats to histamine or
excite them directly at higher doses [103].
It is generally believed and stated in many reviews that human
intestinal mast cells do not release serotonin. This would be supported
by our own results which show a consistent lack of serotonin
immunoreactivity in human intestinal mast cells (Fig. 1). Also
human isolated mast cells do not release serotonin in response to IgE
receptor cross linking (personal communication Prof. Stephan Bis-
choff, UniversityHohenheim). However, there is no original paper that
actually substantiates the assumption that human intestinal mast cells
cannot release serotonin. There are two publications that demonstrate
presence of serotonin in human intestinal mast cells. The ﬁrst paper
described the presence of serotonin immunoreactivity in about 30% of
mast cells in normal tissue from patients with rectal carcinoma [49].
Their number is increasedmore than threefold in the colon of patients
with UC. This study also showed an electronmicrograph of a serotonin
containingmast cell degranulating in the lumen of a gland. The second
paper reported that cultured human mast cells derived from CD34+
peripheral blood progenitors are able to release serotonin although the
serotonin levels were much smaller than those released from mouse
mast cells [104]. The same study also found that human mast cells
express the serotonin synthesizing enzyme tryptophan hydroxylase.
Thus the jury is still out on the ability or inability of mast cells to
synthesize and release serotonin. In case it turns out that mast cells do
under certain conditions or in response to a particular stimulus release
serotonin, this serotonin may then act on nerves nearby. Humaning patterns such as those shown in Fig. 1 and functional data. The diagram takes into
epithelial layer. Mast cell mediators excite enteric neurons through the receptors listed.
mitters released from enteric nerves or visceral afferents modulate mast cell mediator
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mediated primarily by 5-HT3 receptors [105].
Proteases, in particular the serine protease tryptase, are prominent
mediators released from mast cells. Tryptase is present in almost all
humanmast cells, comprising up to 25% of their total proteins [106]. In
patients with UC tryptase induces the production and release of
inﬂammatory cytokines and chemokines [107] some of which may
exert their effects through nerve pathways as outlined above.
Proteases signal to nerves through proteinase-activated receptors
(PARs) [108–110]. So far four cloned PAR receptors have been
identiﬁed in humans. PAR1 and PAR3 are predominantly activated
by thrombin, PAR2 is activated by trypsin andmast cell tryptase, PAR4
has equal afﬁnity for thrombin and trypsin [111–113]. Guinea-pig ENS
expresses PAR1, PAR2 and PAR4 which mediate activation of enteric
neurons [114,115]. Recent studies focused on the role of neural PAR2
in various animal models. Thus PAR2 activation in mice increases
intestinal permeability, which is mediated by SP and capsaicin-
sensitive spinal afferent nerves [116]. In rats PAR2 activation evoked
visceral hypersensitivity [117]. There are somenoteworthy differences
in the action of PAR activating peptides in the human ENS: PAR1
activation is the most important neural pathway; PAR4 activation
occurs only in a minority of neurons while PAR2 activation is almost
negligible [118]. The functional relevance of this effect was demon-
strated by the ﬁnding that only PAR1 but not PAR2 activation leads to
increased nerve-dependent secretion in human intestinal mucosa/
submucosa preparations. A schematic illustration and summary of
mast cell–nerve interactions in the human gut is given in Fig. 2.
7. Functional relevance of mast cell nerve interactions for
translational neurogastro-enterology
The concentration of histamine and proteases is increased in
supernatants from mucosal biopsies of IBS patients [74,75] and
supernatants from stool of IBS and UC patients contain increased
protease levels [119]. In both diseases an increased density of mucosal
mast cells in close proximity to nerve endings [120], as well as an
increased concentration of the mast cell products histamine and
tryptase, and also certain cytokines and prostaglandins were found in
the mucosa [40,64,77,120–124]. The increased concentration of mast
cell mediators in the diseased gut may sensitize enteric neurons as
well as visceral afferents. Thus mucosal biopsy supernatants from IBS
patients activate human enteric neurons [75]. Histamine and in
particular proteases play a major role in this activation which may
explain alterations of gut functions in IBS patients. The same super-
natants do also activate rat visceral afferents [74], an action that may
contribute to visceral hypersensitivity. It is noteworthy that the mast
cell stabilizer ketotifen improves the symptom score in IBS patients
[78].
Likewise, mucosal biopsy supernatants from UC patients activate
mouse DRG neurons innervating colon [125]. The keymediator here is
TNFα. A possible TNFα contribution to the excitatory actions of IBS
supernatants has not been tested. Likewise the contribution of
histamine and proteases has not been tested for UC supernatants. It
is therefore not possible to conclude at this stage on whether the
underlying mechanisms responsible for the excitatory actions of IBS
or UC supernatants are different.
8. Concluding remarks
There is clear evidence for functional mast cell to nerve signaling
and nerve to mast cell signaling in the human intestine. While
activation of mast cells cause mostly nerve sensitization nerves can
activate or inhibit mast cell mediator release. It is suggested that these
interactions play an important role in symptom generation or even
pathogenesis of functional and inﬂammatory bowel disorders.References
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